Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population – Phase 2 (Real-life effectiveness of Flutiform - Phase 2)

First published 16/10/2014

Last updated 17/03/2015

EU PAS number:

EUPAS7641

Study

Finalised

Documents

Study protocol

Initial protocol

2014_10_16 RiRL Study Protocol_phase2_ENCEPP

English (416.7 KB - PDF) View document

Study results

2014_01_07_REG_SUMMIT_R03212b_FLUTIFORM_Phase2_FULL_FINAL_ver4.0_clean

English (74.35 KB - PDF) View document

Study report

Other information

Publications

Study publications

Secondary tabs